Sanofi gains exclusivity rights to Ventyx's CNS-penetrant drug in $27m deal

By Yahoo! Finance | Sep 23, 2024 at 01:56 PM EST

Sanofi secures exclusive rights to Ventyx Biosciences' CNS-penetrant candidate VTX3232 in a $27 million deal. This agreement grants Sanofi first negotiation rights for the potential neuroinflammatory treatment, boosting Ventyx's stock prices by 14.8%.

Did you find this insightful?

Bad

Just Okay

Amazing

We are preparing, please wait

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.